A 45-year-old man with end-stage renal disease secondary to hypertension presented with abdominal pain, nausea, vomiting, and fever. He had been on peritoneal dialysis for 15 years.
/L (3.70-11.0). Blood cultures were negative. Peritoneal fl uid analysis showed a white blood cell count of 1.2 × 10 9 /L (reference range < 0.5 × 10 9 /L) with 89% neutrophils, and an amylase level less than 3 U/L (reference range < 100). Fluid cultures were positive for coagulase-negative staphylococci and Staphylococcus epidermidis.
Computed tomography (CT) showed diffuse parietal and visceral peritoneal calcifi cations encasing the small-bowel loops, consistent with encapsulating peritoneal sclerosis (Figure 1) . His peritoneal dialysis catheter was removed, and he was transitioned to hemodialysis. He was discharged on a course of antibiotics and was started on prednisone and tamoxifen.
He presented again a few months later with abdominal pain. 
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moperitoneum consistent with bowel perforation. He declined surgical treatment and was referred for hospice care.
■ CAUSES AND CLINICAL FEATURES
Encapsulating peritoneal sclerosis is a devastating complication of peritoneal dialysis, occurring in 3% of patients on peritoneal dialysis. The mortality rate is above 40%.
1,2 It is characterized by an initial infl ammatory phase followed by extensive intraperitoneal fi brosis and encasement of bowel. Causes include prolonged exposure to peritoneal dialysis or glucose degradation products, a history of severe peritonitis, use of acetate as a dialysate buffer, and reaction to medications such as beta-blockers. 3 Clinical features result from infl ammation, ileus, and peritoneal adhesions and include abdominal pain, nausea, and vomiting.
A high peritoneal transport rate, which often heralds development of encapsulating peritoneal sclerosis, leads to failure of ultrafi ltration and to fl uid retention.
CT is recommended for diagnosis and demonstrates peritoneal calcifi cation with bowel thickening and dilation.
■ TREATMENT
Treatment entails stopping peritoneal dialysis, changing to hemodialysis, bowel rest, and corticosteroids. Successful treatment has been reported with a combination of corticosteroids and azathioprine. 4, 5 A retrospective study showed that adding the antifi brotic agent tamoxifen was associated with a decrease in the mortality rate. 6 Bowel obstruction is a common complication, and surgery may be indicated. Enterolysis is a new surgical technique that has shown improved outcomes. 7 
■
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